Login to Your Account



PHASE I/II TRIAL UNDER WAY

Ignyta firing up IPO: $44M for cancer bid with kinase inhibitors

By Randy Osborne
Staff Writer

Friday, March 14, 2014
Already trading weakly as a public entity thanks to its reverse merger in the fall of last year, Ignyta Inc. priced an initial public offering (IPO) of about 5.2 million shares at $9.15 each, for gross proceeds of about $48 million and a net haul of about $44.5 million.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription